COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients (FIL_GEMRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01822886
Recruitment Status : Completed
First Posted : April 2, 2013
Results First Posted : October 10, 2019
Last Update Posted : October 14, 2019
Information provided by (Responsible Party):
Fondazione Italiana Linfomi ONLUS

Brief Summary:
Pilot clinical trial - Phase 2a, multicenter, single arm, open label trial - to evaluate efficacy and safety of concomitant combination treatment with Gemcitabine and Romidepsin (GEMRO) regimen as salvage treatment in relapsed/refractory PTCL (peripheral T-cell lymphoma) in a selected population of patients.

Condition or disease Intervention/treatment Phase
Peripheral T-cell Lymphoma Drug: Romidepsin + Gemcitabine Phase 2

Detailed Description:
Objectives will be focused on preliminary dose-response, type of patients, frequency of dosing, and safety and tolerability profile.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients.
Actual Study Start Date : January 2013
Actual Primary Completion Date : December 2014
Actual Study Completion Date : July 2018

Arm Intervention/treatment
Experimental: Romidepsin, Gemcitabine
Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD (progression disease)
Drug: Romidepsin + Gemcitabine
Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD

Primary Outcome Measures :
  1. Complete Remission (CR) Rate [ Time Frame: 18 months ]
    Complete Remission is disappearance of all target lesions per the Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007)"

Secondary Outcome Measures :
  1. Percentage of Participants With Progression-Free Survival [ Time Frame: 24 months ]
    The time from start of study treatment to first documentation of objective tumor progression or to death due to any cause, whichever comes first. PFS (progression-free survival) data will be censored on the day following the date of the last radiological assessment of measured lesions documenting absence of progressive disease for patients who do not have objective tumor progression and are still on study at the time of an analysis, are given antitumor treatment other than the study treatment or stem cell transplant, or are removed from study prior to documentation of objective tumor progression. Patients lacking an evaluation of tumor response after their first dose will have their event time censored at 1 day. Percentage of participants is an estimate based on Kaplan-Meier method.

  2. Overall Survival is Measured From the Date of Study Entry to the Date of Patient's Death [ Time Frame: 24 months ]
    OS (overall survival) is measured from the date of study entry to the date of patient's death. If the patient is alive or his vital status is unknown, the date of death will be censored at the date that the patient is last known to be alive.

  3. Safety - Frequency of Toxicities Grade 3 and 4 [ Time Frame: 24 months ]
    Frequency of toxicities was reported by type and grade according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).

  4. Overall Response Rate (ORR) [ Time Frame: 24 months ]
    ORR the proportion of patients who achieve CR (complete response), CRu (complete remission unconfirmed) or PR (partial response) relative to the per-protocol population. Disease response and progression will be evaluated according to the "Revised Response Criteria" for malignant lymphoma (Cheson et al. 2007).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histological diagnosis of PTCL according to the WHO (World Health Organization) classification
  • Age ≥ 18 years
  • Relapsed (≥1) or refractory to conventional chemotherapy/radiotherapy
  • Stage I-IV according to the Ann Arbor staging System
  • ECOG (Eastern Cooperative Oncology Group) Performance status ≤2
  • Normal renal and hepatic functions
  • Laboratory test results as follows:

    • Serum creatinine ≥ 2.0 mg/dL
    • Total bilirubin ≥ 1.5 mg/dL
    • AST (SGOT) and ALT (SGPT) £2 x ULN or £5 x ULN if hepatic metastases are present
    • Negative HIV HCV and HBV status
  • Adequate bone marrow reserve: Platelet count>100X109 cells/L or platelet count <75X109 cells/L if bone marrow disease involvement, absolute neutrophile count (ANC)> 1,5 X109, hemoglobin>8 g/dl.
  • Able to adhere to the study visit schedule and other protocol requirements
  • Cardiac ejection fraction (MUGA scan or echocardiography) > 45%
  • Life expectancy > 6 months
  • Females of childbearing potential (FCBP) must have a negative serum or urine β-hCG pregnancy test result within 7 days prior to the first dose of study drug. Females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy
  • Both females of childbearing potential and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days after the last dose of study drug.
  • Measurable disease of at least 2 cm as detected by CT scan, assessed by site radiologist
  • Patients or they legally authorized representative must provide written informed consent

Exclusion Criteria:

  • Any serious active disease or co-morbid medical condition (according to investigator's decision)
  • Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥ 3 years
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
  • Patients with congenital long QT syndrome, history of significant cardiovascular disease and/or taking drugs leading to significant QT prolongation
  • Corrected QT interval > 480 msec (using the Fridericia formula)
  • Low K+ (<3.8 mmol/L) and low Mg+ (<0.85 mmol/L) levels, except if corrected before beginning the chemotherapy
  • Pregnant or lactating females or men or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study
  • Previous exposure to romidepsin or gemcitabine
  • CNS disease (meningeal and/or brain involvement by lymphoma) or testicular involvement
  • History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
  • Active opportunistic infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01822886

Layout table for location information
A.O. SS. Antonio e Biagio e C. Arrigo
Alessandria, Italy, 15121
Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola
Bologna, Italy, 40138
Fondazione IRCCS Istituto Nazionale dei Tumori
Milano, Italy, 20133
A.O. Universitaria Citta' Della Salute E Della Scienza Di Torino
Torino, Italy, 10126
Sponsors and Collaborators
Fondazione Italiana Linfomi ONLUS
Layout table for investigator information
Principal Investigator: Pier Luigi Zinzani Istituto Ematologia e Oncologia Medica "SERAGNOLI" Università di Bologna

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Fondazione Italiana Linfomi ONLUS Identifier: NCT01822886    
Other Study ID Numbers: FIL_GEMRO
First Posted: April 2, 2013    Key Record Dates
Results First Posted: October 10, 2019
Last Update Posted: October 14, 2019
Last Verified: August 2018
Keywords provided by Fondazione Italiana Linfomi ONLUS:
T-cell lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic